Okami Medical has closed a financing round, raising $32.5m led by Vensana Capital, with contributions from US Venture Partners and other industry veterans.
This capital injection will expedite the development and commercialisation of Okami’s catheter-based technologies for peripheral vascular occlusion.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The investment underscores the potential of Okami’s LOBO Vascular Occlusion System and SENDERO Microcatheter, which, according to the company, are set to transform interventional procedures for peripheral arterial targets.
The LOBO system offers a single-device solution for a wide range of vessel sizes, streamlining the occlusion process for interventional physicians.
Okami CEO and president Rhonda Robb said: “We are honoured to have the support of Vensana and our existing investors to advance these important technologies and deliver them to patients.
“We are also grateful for the support and contributions of our employees and physician partners as we work tirelessly to build the market leader in vascular occlusion.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOkami’s advanced HDBRAID technology is a key feature of the LOBO system, creating an effective pore structure that significantly diminishes blood flow to facilitate rapid vessel closure.
This technology is expected to improve treatment outcomes for various medical conditions by enabling efficient blood vessel closure throughout the body.
In addition to the LOBO system, Okami has developed the SENDERO Microcatheter, which boasts FDA 510(k) clearance.
The SENDERO is engineered for optimal delivery of interventional devices such as LOBO-3 and LOBO-5 and features a hydrophilic coating, stainless steel braid, and radiopaque marker band for enhanced trackability and precise device placement.
Vensana Capital partner Mike Kramer and managing partner Kirk Nielsen commented: “LOBO and SENDERO address many of the shortcomings of traditional coils and vascular plugs. Designed for predictable, rapid, and durable occlusion, the platform represents a meaningful step forward in the treatment of vascular disease.”
The funding will also support further innovation at Okami Medical, which was established in 2017 by Inceptus Medical, a medical device incubator.
